An interventional study of MRI acquisition and behavioral evaluations in Parkinson's Disease and Multiple System Atrophy, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-09.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Diagnostic
Based on previous promising results, the next step for the validation of a multimodal MRI method in diagnosis and follow up of patients reached by parkinsonian syndromes is (i) to test whether the multimodal neuroimaging is able to discriminate at the individual level, patients with multiple system atrophy parkinsonism (MSA) and patients with idiopathic Parkinson's disease (PD) (ii) to determine whether the method is sensitive to measure changes over time for the two diseases, according to imaging, neuropsychological and other clinical data. Patients will be compared with healthy controls.
30 patients with PD, 30 patients with MSA and 30 healthy controls will be examined in a 3Tesla MRI.
The aim of our project is to demonstrate that our multimodal MRI method can discriminate both diseases with a similar clinical presentation and monitor the progress of the disease. CIC's expertise in recruitment and assessment of patients, and the powers of the INSERM U825 in terms of development and processing in neuroimaging guarantee the feasibility of the project and its successful completion.
4,487 studies on the registry are indexed under Parkinson Disease; 1,081 are open to participants now.
This study's enrollment of 94 is above the median of 40 across 3,293 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
Other: MRI acquisition · Behavioral: behavioral evaluations
Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
Other: MRI acquisition · Behavioral: behavioral evaluations
30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit
Other: MRI acquisition · Behavioral: behavioral evaluations
MRI acquisitions
Evaluations about motor abilities, sleep, cognition and lifestyle
The primary outcome measure to discriminate individual patients and patients with MPI and AMS through multimodal MRI isolating multiparametric spatial signature resulting from a combination of markers in multimodal imaging.
Time frame: 1 year
correlate MP and MSA disease severity with extracted multimodal MRI biomarkers in whole brain
Time frame: 1 year
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France